Skip to main content

Published locations for Dr. Pinilla-Ibarz: Trial supports the use of nilotinib 300mg twice daily as front line therapy for CML

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Dr. Pinilla-Ibarz: Trial supports the use of nilotinib 300mg twice daily as front line therapy for CML

User login

  • Reset your password
  • /content/dr-pinilla-ibarz-trial-supports-use-nilotinib-300mg-twice-daily-front-line-therapy-cml
  • /hematology-oncology/article/235806/cml/dr-pinilla-ibarz-trial-supports-use-nilotinib-300mg-twice